Forum Archive Index - July 2001

["G Stolwyk" <stolwyk@wave.co.nz>]

Thank you, Andrew!

 

Good introductory reading for potential investors!

 

The  Novacor device was mentioned in conjunction with trials for longer term use.

 

Dr. Woodard, the CEO of MMD ( Australia )  was in charge of the blood path design team for the current version of the  Novacor heart assist device.

 

He was involved in pre-clinical animal testing, clinician training and the successful launch of the Novacor device in Europe.

 

The MMD design has not been directly referred to by your Fool's writer but has now been fully patented in the US by MMD. 

 

Why the design with resulting mimimal damage to blood, is so desirable, has been summarized by me on the MMD Message Board of Ozestock, see posts 340 and 1069.

 

The latter is an update. Or, one can get most of this info from the MMD web site < www.micromed.com.au >. 

 

I am not the least worried about the potential commercial and financial returns of this Rolls-Royce of Heart Assist devices!

 

There are two hurdles to overcome:

1.The success or otherwise of the human trials.

 

2.The great possibility that MMD will be taken over when signs indicate that the trials will be successful.

 

The latter is worrying as any benefits to investors will go off-shore!

 

( Obviously, any take-over price will be significant and I am fully aware of that! )

 

MMD for their part will look for close associations to prevent this, but the share register is an open one!

 

Gerry

Holds MMD.

Disclaimer: Readers are not asked to buy, hold or sell MMD stock. To do so will be entirely at their own risk.